Pregabalin Capsule
Product Images NDC 72205-011

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72205-011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Equation (Pregabain Gault Equation)

The image shows a formula for calculating creatinine clearance (CLCr), including adjustments for age, weight, serum creatinine, and a multiplication factor for female patients. This formula is typically used in pharmacokinetics to estimate renal function and adjust medication dosing.*

FDA Label Image

100-mg-90s (Pregabalin 100 mg 90s Count)

Label for Pregabalin Capsules 100 mg by Novadoz Pharmaceuticals LLC, indicating a package of 90 capsules. The label includes storage instructions, manufacturer (MSN Laboratories Private Limited, India), distributor details, an NDC number 72205-014-90, and a medication guide website.*

FDA Label Image

150-mg-90s (Pregabalin 150 mg 90s Count)

Label for Pregabalin Capsules 150 mg oral dosage form, containing 90 capsules. The product is distributed by Novadoz Pharmaceuticals LLC, with manufacturing by MSN Laboratories Private Limited in India. The label includes storage instructions, dosage information, and a medication guide note. The label also shows the NDC 72205-015-90 and branding for Novadoz Pharmaceuticals.*

FDA Label Image

200-mg-90s (Pregabalin 200 mg 90s Count)

Label for Pregabalin Capsules 200 mg in a 90-capsule package by Novadoz Pharmaceuticals LLC. The label states storage instructions, manufacturing details by MSN Laboratories Private Limited in India, and includes a barcode and medication guide information. Capsules are oral prescription drug form.*

FDA Label Image

225-mg-90s (Pregabalin 225 mg 90s Count)

Label for Pregabalin Capsules 225 mg in a container of 90 capsules, manufactured by MSN Laboratories Private Limited and distributed by Novadoz Pharmaceuticals LLC. The label includes storage instructions and a note to dispense the accompanying medication guide, with the Novadoz logo and contact information.*

FDA Label Image

25-mg-90s (Pregabalin 25 mg 90s Count)

Pregabalin Capsules 25 mg oral capsules label for a 90-capsule bottle. The label includes storage instructions, manufacturer MSN Laboratories Private Limited (India), and distributor Novadoz Pharmaceuticals LLC (Piscataway, NJ). It notes Rx only status and medication guide availability at NovadozPharma.com.*

FDA Label Image

300-mg-90s (Pregabalin 300 mg 90s Count)

Pregabalin Capsules 300 mg oral capsules label showing a 90-capsule package by Novadoz Pharmaceuticals LLC. The label includes storage instructions, prescription-only status, manufacturer MSN Laboratories in India, and a note to dispense the accompanying medication guide.*

FDA Label Image

50-mg-90s (Pregabalin 50 mg 90s Count)

Label for Pregabalin Capsules 50 mg in a 90-capsule package. The label includes storage instructions, manufacturer (MSN Laboratories Private Limited, India), and distributor (Novadoz Pharmaceuticals LLC, Piscataway, NJ). It mentions dispensing the accompanying medication guide and displays the Novadoz logo with contact information and barcodes.*

FDA Label Image

75-mg-90s (Pregabalin 75 mg 90s Count)

Pregabalin Capsules 75 mg label for a package containing 90 capsules. The label shows storage instructions at 25°C (77°F) with permitted excursions, dispensing instructions, and the manufacturer MSN Laboratories Private Limited in India. Distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. Includes a barcode and contact information for Novadoz Pharmaceuticals.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Four lines represent different treatment groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph illustrates varying degrees of pain improvement associated with each dose over the range from 0 to 100 percent.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier cumulative response curve compares the percent of patients improved at various thresholds of percent improvement in pain from baseline between Pregabalin 100 mg three times a day and placebo. The y-axis shows percent of patients improved, and the x-axis shows percent improvement in pain from baseline, segmented at intervals from over 0% to 100%.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

Kaplan-Meier plot showing the percent of patients improved versus percent improvement in pain from baseline in a study of Pregabalin capsules taken orally at doses of 75 mg, 150 mg, and 300 mg twice a day, compared to placebo. The graph depicts the cumulative proportion of patients experiencing different levels of pain improvement over the range from 0% to 100%.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A Kaplan-Meier curve graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The y-axis represents the percent of patients improved and the x-axis shows the percent improvement in pain from baseline, ranging from >0 to 100%.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The graph illustrates the distribution of patient-reported pain improvements across these treatments.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart comparing responder rates (%) in two studies, Study E1 and Study E3. Study E1 shows responder rates for placebo, and Pregabalin doses of 50 mg, 150 mg, 300 mg, and 600 mg taken twice daily (BID). Study E3 shows responder rates for placebo and Pregabalin 600 mg taken twice daily (BID) and three times daily (TID). The chart includes sample sizes (N) for each group and indicates statistically significant differences versus placebo.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A dose-response line graph showing median percent seizure reduction from baseline on the y-axis against dose in mg/day on the x-axis. Four treatment groups are depicted with different symbols representing Stukly E1BID, E2BID, E3BID, and E3TID dosing regimens. The graph shows increasing seizure reduction with higher doses, and statistical significance (p-values) is indicated next to several data points.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A line graph depicting percent of patients improved against percent improvement in pain from baseline for Pregabalin doses of 600 mg, 450 mg, and 300 mg daily, compared with placebo. Four curves show decreasing patient improvement percentages as pain improvement increases from 0 to 100%.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The Y-axis shows the estimated percentage without LTR from 0% to 100%, and the X-axis shows days from 0 to 180. Two lines represent Pregabalin (solid) and placebo (dashed).*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percentage of subjects improved over time for Pregabalin and placebo groups. The x-axis shows percent improvement from baseline to week 12 BOCF, and the y-axis shows the percent of subjects improved. Pregabalin is represented by a solid line, and placebo by a dotted line, illustrating higher subject improvement percentages with Pregabalin.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing the percent of subjects improved between Pregabalin and Placebo from baseline to Week 16. The x-axis represents percent improvement, while the y-axis shows the percent of subjects improved. Two lines are shown: a solid line for Pregabalin and a dashed line for Placebo, illustrating relative improvement percentages over time.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of Pregabalin showing its molecular arrangement with functional groups including an amino group and a carboxyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.